Yan Liu1, Xiao-Feng Yu1, Jian Zou1, Zi-Hua Luo1. 1. Yan Liu, Xiao-Feng Yu, Jian Zou, Zi-Hua Luo, Department of Gastroenterology, Huadong Hospital, Fudan University, Shanghai 200040, China.
Abstract
AIM: To assess the prognostic value of c-Met status in colorectal cancer. METHODS: We conducted a search in PubMed, Web of Science, and the Cochrane Library covering all published papers up to July 2014. Only studies assessing survival in colorectal cancer by c-Met status were included. This meta-analysis was performed by using STATA11.0. RESULTS: Ultimately, 11 studies were included in this analysis. Meta-analysis of the hazard ratios (HR) indicated that patients with high c-Met expression have a significantly poorer overall survival (OR) (HR = 1.33, 95%CI: 1.06-1.59) and progression-free survival (PFS) (HR = 1.47, 95%CI: 1.03-1.91). Subgroup analysis showed a significant association between high c-Met expression and poorer overall survival in the hazard ratio reported (HR = 1.41, 95%CI: 1.08-1.74). CONCLUSION: The present meta-analysis indicated that high c-Met expression was associated with poor prognosis in patients with colorectal cancer.
AIM: To assess the prognostic value of c-Met status in colorectal cancer. METHODS: We conducted a search in PubMed, Web of Science, and the Cochrane Library covering all published papers up to July 2014. Only studies assessing survival in colorectal cancer by c-Met status were included. This meta-analysis was performed by using STATA11.0. RESULTS: Ultimately, 11 studies were included in this analysis. Meta-analysis of the hazard ratios (HR) indicated that patients with high c-Met expression have a significantly poorer overall survival (OR) (HR = 1.33, 95%CI: 1.06-1.59) and progression-free survival (PFS) (HR = 1.47, 95%CI: 1.03-1.91). Subgroup analysis showed a significant association between high c-Met expression and poorer overall survival in the hazard ratio reported (HR = 1.41, 95%CI: 1.08-1.74). CONCLUSION: The present meta-analysis indicated that high c-Met expression was associated with poor prognosis in patients with colorectal cancer.
Authors: Murray B Resnick; Justin Routhier; Tamako Konkin; Edmond Sabo; Victor E Pricolo Journal: Clin Cancer Res Date: 2004-05-01 Impact factor: 12.531
Authors: Sun Jin Kim; Marjorie Johnson; Kristen Koterba; Matthew H Herynk; Hisanori Uehara; Gary E Gallick Journal: Clin Cancer Res Date: 2003-11-01 Impact factor: 12.531
Authors: Conor A Bradley; Manuel Salto-Tellez; Pierre Laurent-Puig; Alberto Bardelli; Christian Rolfo; Josep Tabernero; Hajrah A Khawaja; Mark Lawler; Patrick G Johnston; Sandra Van Schaeybroeck Journal: Nat Rev Clin Oncol Date: 2017-04-04 Impact factor: 66.675
Authors: Aiwu Ruth He; Roger B Cohen; Crystal S Denlinger; Ashwin Sama; Ariel Birnbaum; Jimmy Hwang; Takami Sato; Nancy Lewis; Michelle Mynderse; Michele Niland; Jennifer Giles; Johan Wallin; Brian Moser; Wei Zhang; Richard Walgren; Elizabeth R Plimack Journal: Oncologist Date: 2019-03-04
Authors: Mansoor Saleh; Philippe A Cassier; Lauriane Eberst; Gurudatta Naik; Van K Morris; Shubham Pant; Catherine Terret; Ling Gao; Amanda Long; Huzhang Mao; Samuel McNeely; Erin K Wagner; Roberto M Carlesi; Siqing Fu Journal: Oncologist Date: 2020-07-17
Authors: Wenyuan Xiong; Manja Friese-Hamim; Andreas Johne; Christopher Stroh; Manfred Klevesath; Gerald S Falchook; David S Hong; Pascal Girard; Samer El Bawab Journal: CPT Pharmacometrics Syst Pharmacol Date: 2021-05-01
Authors: Wafaa M Rashed; Mohamed A Kandeil; Mohamed O Mahmoud; Doha Maher; Sameera Ezzat; Mohamed H Abdel-Rahman Journal: J Cancer Res Clin Oncol Date: 2020-09-26 Impact factor: 4.553